Ophthalmic Drugs London, England, UK 28-29 November 2017

Description:
SMi Group are delighted to introduce Ophthalmic Drugs which is being held on the 28th - 29th November 2017 at the Copthorne Tara Hotel in London, UK.

With the Ophthalmic Drugs market being worth over $37bn in 2026 (Vision Gain), Ophthalmic Drugs 2017 will enable you to explore novel approaches into treatments, new developments in medical devices, drug delivery and pre-clinical and clinical trials in order to deepen your understanding of inherited ocular diseases.

Here's a snap shot of our industry leading experts presenting this November:

- Naj Sharif, Executive Director in RandD, Head, Global Alliances and External Research, Santen Inc
- Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
- Michael Lai, Global Program Medical Director, Novartis
- Sergio Leal, Ophthalmologist Director, Global Clinical Leader, Bayer
- Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
- Amir Shojaei, Vice President Therapeutic Area Head, Ophthalmology, Shire
- Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics

Take a look at the full speaker line-up! www.ophthalmicdrugs.com/evvnt

- Some of the key topics addressed will involve:
- Novel approaches to the treatment of ocular diseases
- Advancements in ophthalmic clinical trials
- Combating challenges in drug release and delivery
- Animal models and regulatory considerations
- Commercial potential of ocular drugs and improved patient care

Time: 08:00 to 17:00

Price:
Standard Price (early-bird rates available): GBP 1499